Navigation Links
Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
Date:6/13/2011

MINNEAPOLIS, June 13, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell 3000® Index and the Russell Global® Index posted by Russell Investments on June 10, 2011 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 24, 2011.  

"The preliminary addition of Uroplasty to the Russell 3000 and Russell Global indexes is a testament to the progress we have made in building valuation," said David Kaysen, president and CEO of Uroplasty.  "It should help expand awareness of our company, especially among institutional investors, as we continue to execute our growth strategy for our Urgent PC® and Macroplastique® product lines."

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell Global Index measures the performance of the global equity market based on all investable equity securities, and includes approximately 10,000 securities in 48 countries and covers 98% of the investable global market. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies.  The indexes are reconstituted annually.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140


EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
2. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
3. Uroplasty to Present at the JMP Securities Research Conference
4. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
5. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
6. Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
7. Uroplasty Reports Financial Results for the Third Quarter FY2011
8. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
9. Uroplasty Announces Addition of Robert Kill to its Board of Directors
10. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
11. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):